Skip to content

Topical application of UV-irradiated "Vitamin D" on implant surface during implantation for the evaluation of Osteoprotegerin (OPG) and implant stability: A Randomized control study

Assessment of Osteoprotegerin (OPG) and implant stability through the Topical application of UV irradiated Vitamin D on implant surface during placement :A Randomized controlled clinical trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/02/063034
Enrollment
20
Registered
2024-02-22
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K068- Other specified disorders of gingiva and edentulous alveolar ridge

Interventions

Intervention1: vitamin D: for implant placement in test group Prophylactic antibiotic coverage of 2 gm Amoxycillin will be given to all the subjects 1 hour before the procedure. After local anesthesia

Sponsors

King georges medical university
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with edentulous space in the maxillary jaw having healed bone site indicated for rehabilitation with implants. 2. Patient having sufficient residual bone volume for implant placement. 3. Patient having good general health with no systemic disease. 4. Patient having adequate oral hygiene. 5. Good general and periodontal health.

Exclusion criteria

Exclusion criteria: 1. Patients who consume alcohol, smoke or use illicit drugs. 2. Patient with any systemic disease, irradiated patients, patients with previous or active treatments with steroids or bisphosphonates 3. Pregnant/lactating women 4. Systemic diseases which can affect bone metabolism such as osteoporosis and endocrine diseases 5. Patients taking antibiotics/steroids/anti inflammatory for the past 3 months.

Design outcomes

Primary

MeasureTime frame
osteoprotegerin biomarker Timepoint: 0 weeks, 2 weeks, 12 weeks

Secondary

MeasureTime frame
implant stability crestal bone lossTimepoint: 0 weeks, 2 weeks, 12 weeks, 6 months

Countries

India

Contacts

Public ContactDr Ruby Singh

King Georges medical university

drjit123@rediffmail.com9415576398

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026